ARENTFOX SCHIFF LLP for TRANSPARENCY-RX CORP.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 13, 2026 | $20,000 | Replaced |
| 2nd Quarter - Termination | Oct 19, 2026 | $20,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pharmacy Benefit Manager reform Transparency in prescription drug markets Prescription drug prices H.R.7148 (Consolidated Appropriations Act, 2026), regarding Pharmacy Benefit Manager reform, transparency in prescription drug markets, and prescription drug prices H.R. 6609 and H.R. 6610 (Pharmacists Fight Back Act), generally H.R. 5582 and S. 2355 (Patients Deserve Price Tags Act), generally
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| KATHERINE KRAMER | — |
| DANIEL SJOSTEDT | — |
| BLAKE THELANDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.